MedTrace Logo

Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer

NCT02202928 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-12-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of autologous tumor lysate-pulsed dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).

Conditions

  • Colorectal Cancer
  • Neoplasms
  • Intestinal Neoplasms
  • Digestive System Neoplasms
  • Gastrointestinal Diseases

Interventions

BIOLOGICAL

DC-CIK

8×10\^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.

RADIATION

Radiotherapy

45\~50 Gy in 25-28 fractions.

DRUG

Chemotherapy

Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.

Sponsors & Collaborators

  • Jingzhou Central Hospital

    collaborator OTHER

  • Shenzhen Hornetcorn Bio-technology Company, LTD

    lead INDUSTRY

Principal Investigators

  • Ke N Zhang, Professor · Jingzhou Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02202928 on ClinicalTrials.gov